IM2PACT is a consortium of 27 international partners from academia, industry, and small and medium enterprises, which aims to tackle the unmet challenge of discovery and characterization of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases. The blood-brain barrier is a protective layer between the brain’s blood capillaries and the cells that make up brain tissue. This barrier provides a defense against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing across into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies. Artemis Bio-Support is in charge of understanding the mechanisms of transcytosis and translating this knowledge in development of nanoparticles that exploit this mechanism to enter the brain. Such delivery systems will then be used by other partners to develop new treatments against neurodegenerative diseases.